22 23 Classification: BIOLOGICAL SCIENCES: Microbiology; Biophysics and Computational Biology 24 25 ABSTRACT 34 35 The rapid spread of multi-drug resistant strains has created a pressing need for new drug 36 regimens to treat tuberculosis (TB), which kills 1.8 million people each year. Identifying new 37 regimens has been challenging due to the slow growth of the pathogen M. tuberculosis (MTB), 38 coupled with large number of possible drug combinations. Here we present a computational 39 model (INDIGO-MTB) that identified synergistic regimens featuring existing and emerging anti-40 TB drugs after screening in silico over 1 million potential drug combinations using MTB drug 41 transcriptomic profiles. INDIGO-MTB further predicted the gene Rv1353c as a key 42 transcriptional regulator of multiple drug interactions, and we confirmed experimentally that 43 Rv1353c up-regulation reduces the antagonism of the bedaquiline-streptomycin combination. 44 Retrospective analysis of 57 clinical trials of TB regimens using INDIGO-MTB revealed that 45 synergistic combinations were significantly more efficacious than antagonistic combinations (p-46 value = 1 x 10 -4 ) based on the percentage of patients with negative sputum cultures after 8 47 weeks of treatment. Our study establishes a framework for rapid assessment of TB drug 48 combinations and is also applicable to other bacterial pathogens. 49 50 IMPORTANCE 51 52 Multi-drug combination therapy is an important strategy for treating tuberculosis, the world's 53 deadliest bacterial infection. Long treatment durations and growing rates of drug resistance 54 have created an urgent need for new approaches to prioritize effective drug regimens. Hence, 55 we developed a computational model called INDIGO-MTB, which identifies synergistic drug 56 regimens from an immense set of possible drug combinations using pathogen response 57 transcriptome elicited by individual drugs. Although the underlying input data for INDIGO-MTB 58 was generated under in vitro broth culture conditions, the predictions from INDIGO-MTB 59 correlated significantly with in vivo drug regimen efficacy from clinical trials. INDIGO-MTB also 60
INTRODUCTION 72
Tuberculosis (TB) is a global health threat of staggering proportions, taking a human life every 73 30 seconds (1). To ensure adequate treatment and combat onset of resistance, TB patients 74 receive multidrug therapy. However, the frontline regimen of four drugs and six months 75 treatment has not changed in 50 years, and resistance is spreading. In response, experts have 76 called for entirely new regimens to combat the TB pandemic (2). While some new anti-TB 77
agents are beginning to emerge (3), optimizing individual agents into effective regimens remains 78 a significant challenge. 79
At present, combinations are designed and tested empirically, driven in part by clinical intuition. 80
A standard approach to evaluate drug interactions experimentally utilizes checkerboard assays, 81
which involves exposing the pathogen to different dose combinations of constituent drugs in a 82
regimen. New approaches have been developed to increase throughput of checkerboard 83 assays, either by reducing the number of doses required or by using computational optimization 84
to find optimal doses (4-6). 85
Even with these developments, the enormous and expanding number of potential drug 86 combinations renders regimen optimization by comprehensive experimental testing infeasible. 87
The 28 drugs used to treat TB (7-10) could be assembled into nearly 24,000 different 3-or 4-88 drug combinations. Adding just two new agents to that list increases the number of different 89 combinations to almost 32,000. Thus, there is a need for high-throughput approaches that can 90
prioritize new drug combinations based on data generated from individual drugs. For example, a 91 feedback-based approach was recently used to determine the optimal dosing of multi-drug 92 regimens (4, 5). However, this approach still requires hundreds of dose-specific measurements 93
for training the algorithm, all of which must be re-done whenever a new agent is under 94
consideration. Computational tools such as metabolic modeling, kinetic modeling, and statistical 95 modeling (11-13) have limited power in this context because direct targets are not known for 96 many compounds. Existing approaches are also limited in the scale at which potential 97 combinations could be evaluated computationallycurrently around hundreds. Furthermore, 98
empirical approaches based on drug similarity (or dissimilarity) are less effective in predicting 99
interaction outcomes for new drugs classes, and they also lack a model for antagonism (14) . 100
Drugs with similar targets can have both synergistic and antagonistic outcomes (14) . 101
To address this challenge, here we extend an in silico tool that we recently created -Inferring 102
Drug Interactions using chemo-Genomics and Orthology, (INDIGO) (14)-to predict 103 synergy/antagonism in combinations of two or more drugs. The original INDIGO model used 104
chemogenomic profiling data under exposure to individual drugs (15, 16) as input data to 105 identify drug-response genes (14) . The scientific premise underlying INDIGO is that drug 106 synergy and antagonism arise because of coordinated, systems-level molecular changes 107
involving multiple cellular processes. Importantly, INDIGO can learn patterns from known drug 108
interactions, which can then be used to forecast outcomes for new drugs and conditions. 109
INDIGO can thus provide insights on underlying mechanism of drug interactions in an unbiased 110 fashion. INDIGO can assess millions of combination regimens without requiring information 111 about the drug target or mode of action. Once an optimal drug regimen can be determined using 112
INDIGO, the dose regimes could be further optimized using feedback-based dose optimization 113 techniques (4, 5). 114
The goal of this study is to identify antibiotic combinations that are most promising for TB drug 115 development. We have adapted INDIGO to make use of transcriptomics data to identify drug-116
response genes, which are more widely available than chemogenomics data for most non-117 model organisms, including Mycobacterium tuberculosis (MTB) (Figure 1) . We then harness a 118 large compendium of publicly available and in-house generated transcriptomics data to show 119 that INDIGO can successfully estimate drug interactions in MTB. We further integrate INDIGO 120 with known MTB gene regulatory networks to identify transcription factors (TFs) that influence 121 the extent of synergy between drugs. False positives and outliers from our model represent 
RESULTS 139

Construction of INDIGO-MTB model from drug response transcriptomes 140
The INDIGO approach requires a list of drug-gene associations and known drug-drug 141 interaction data as input for building a chemical-genetic model of drug interactions. A gene is 142 assumed to have a chemical-genetic association with a drug if a change in its expression leads 143
to a statistically significant alteration in sensitivity to the drug of interest. A drug-gene 144 association network is created by integrating chemogenomic profiling data from hundreds of 145 drugs. This static network is then converted into a predictive model by leveraging the powerful 146 statistical learning tool, Random Forest (17). This algorithm builds decision-trees using genes in 147 the drug-gene association network and identifies those that are predictive of drug interaction 148 outcomes using a training data set. The training data comprises known drug interactions. This 149 trained network model can be used to forecast interactions for novel drug combinations ( Figure  150 1, Figure S1 ). 151
While in the prior study, drug-gene associations were obtained from chemogenomic profiles of 152 E. coli, these comprehensive gene deletion/drug response data are difficult to generate 153 experimentally for most pathogens. We hence hypothesized that transcriptomics data, which 154
quantifies the responses of every gene to a given perturbation, could provide a readily available 155
alternate resource for analysis. This solution could circumvent the limitation that chemogenomic 156
data are not available for most pathogens, including MTB. Generating gene expression data for 157 response to monotherapy drug exposure is straightforward, and there are already publicly 158 available transcriptomic profiles for many anti-TB agents. 159
We compiled transcriptome data profiling MTB response to different compounds and metabolic 160 perturbations from the literature. We augmented this compendium by generating MTB 161 transcriptomic response profiles for emerging TB agents (Methods , Table S1A ). In addition to 162 these transcriptomic data, we also used chemogenomics data from Escherichia coli (16), with E. 163
coli genes matched to corresponding orthologous genes in the MTB genome. Our prior study 164
showed that INDIGO can infer interactions in MTB with significant accuracy using orthologous 165 gene mapping (correlation R = 0.54; p-value = 0.006). This was based on the observation that 166
genes predictive of drug-drug interactions were surprisingly conserved between E. coli and 167
MTB. In cases where multiple datasets profiled the same compound, we prioritized data from 168 MTB profiled with the latest transcriptomics technology whenever possible. We normalized this 169 drug response compendium using the ComBat algorithm (18) to account for inter-study and 170 technology-specific (i.e. microarray, RNAseq) variation in transcriptomics data (Methods). 171
Overall, this compendium contains data for 164 compounds and 65 metabolic perturbations 172 (see Table S1A for full list) (12, 19, 20) . 173
To train INDIGO-MTB, we compiled drug interaction values in MTB for 202 drug combination 174 regimens from the literature, featuring compounds with available chemogenomic or 175 transcriptomic profiles (Table S1B ). The drugs in the training set consist of well-established 176
anti-TB drugs, including rifampicin (RIF), isoniazid (INH), streptomycin (STM), several 177 fluoroquinolones, as well as new drugs such as bedaquiline (BDQ). The extent of interaction 178 between drugs was quantified in these studies by the standard Fractional Inhibitory 179
Concentration (FIC) index (21), or the DiaMOND interaction score (6). In both of these metrics, 180
synergy implies that the same amount of growth inhibition is achieved with a lower dose when 181 both drugs are combined. We used statistical data normalization to combine these datasets, 182 similar to our approach for combining transcriptomics data from various studies and platforms 183
(Methods). This allowed us to account for the new technology-specific variation in drug 184 interaction score distribution. If separate studies in literature provided conflicting interaction 185 scores for a drug combination, we included both values to incorporate this experimental 186 uncertainty into the model. 187
Experimental validation of INDIGO-MTB model 188
The INDIGO-MTB model trained on these drug interaction data was used to infer interaction 189 outcomes for new drugs and regimens . Given that our compendium has 164 compounds and 65  190  perturbations, INDIGO-MTB estimated all 26,106 potential pairwise interactions and all  191 1,975,354 potential three-way interactions. Table S1C shows the entire list of pairwise  192 combinations and interaction scores. 193
We observed striking associations between specific compounds and interactions that were 194
highly synergistic or antagonistic. In particular, combinations containing the drugs 195 chlorpromazine and verapamil were highly enriched for synergistic interactions; 77% of 196 chlorpromazine-containing combinations and 80% of verapamil-containing combinations were 197
found to interact synergistically (FIC < 0.9) ( Figure S2) . Verapamil is an efflux pump inhibitor 198 that influences membrane potential (22) and has been previously been shown to potentiate the 199 activity of several anti-TB drugs (23-25). In contrast, all pairwise combinations featuring 200
sutezolid were found to be antagonistic. 201
Previous work had found combinations of bacteriostatic drugs paired with bactericidal drugs 202
were likely to be antagonistic against E. coli (26). INDIGO-MTB uncovered a similar trend in the 203 MTB drug interactions; combinations featuring a bacteriostatic drug and a bactericidal drug had 204 significantly more antagonistic interaction scores than combinations featuring only bacteriostatic 205 drugs (p < 10 -12 ). Interestingly, combinations featuring only bactericidal drugs also had 206 significantly more antagonistic interaction scores than combinations featuring only bacteriostatic 207 drugs (p < 10 -12 ) ( Figure S2) . 208
To evaluate the accuracy of INDIGO-MTB, we experimentally measured interactions between a 209 set of two-drug and three-drug combinations, and we compared these measurements against 210 the interaction scores from INDIGO-MTB. The compounds featured in the tested combinations 211 are all FDA-approved agents that have diverse mechanisms of action, and are either part of 212 current first-and second-line TB therapy, or have been previously studied for their anti-213 tubercular activity. The interaction outcomes for the test set combinations spanned the entire 214 range of INDIGO-MTB predicted interaction scores, enabling a rigorous assessment of INDIGO-215 MTB (Figure 2A, Figure S3 ). We quantified the interaction outcome either by traditional 216 checkerboard assays or the high-throughput DiaMOND method for three-way combinations 217 (Methods). Given the diverse methodologies used in literature for measuring drug interactions, 218
we included combinations frequently measured in prior literature involving INH, RIF and STM as 219 reference combinations in our test set. In addition, among the test set combinations, 10 220 combinations involved pairwise subsets of three-way combinations that were measured using 221
DiaMOND methodology to infer 3-way interactions. Overall, among the 36 combinations in the 222 experimental validation set, 24 combinations were completely "novel", i.e. never seen by 223
INDIGO. The sample size (N = 24 combinations) for the test set chosen for experimental 224 validation is sufficiently powered to significantly assess the accuracy of INDIGO's correlation 225
with the experimental data (Methods). 226
We first classified experimentally measured combinations as synergistic, additive, or 227
antagonistic. INDIGO-MTB predicted interaction scores were significantly different between 228 these three classes (p-value = 0.0064, Kruskal-Wallis Rank Sum Test, Figure 2C ). In addition, 229
there was a significant difference between INDIGO-MTB predictions for synergistic and 230
antagonistic combinations (p-value = 0.0009, non-parametric Komolgorov-Smirnov test).
231
Receiver Operating Curve (ROC) analysis of INDIGO-MTB predictive performance yielded an 232 area under the curve (AUC) of 0.89 (p = 1.2 x 10 -3 ) and 0.91 (p = 6.7 x 10 -4 ) for detecting 233 synergy and antagonism in the validation set, respectively ( Figure 2D) . These results are robust 234
to the choice of thresholds used for classifying interactions as synergistic or antagonistic 235 ( Figure S4) . We next performed a quantitative comparison between INDIGO-MTB interaction 236 scores and the corresponding in vitro experimentally measured FIC indices using the scale 237 invariant metric, spearman's rank correlation (R) ( Figure 2B ). We observed a high degree of 238 correlation between model prediction and experimental measurements for all combinations (R = 239 0.63, p = 9.5 x 10 -4 ), and also after separating pairwise (R=0.62 ± 0.03, p = 9 x 10 -3 ) and three-240 way interactions (R=0.64 ± 0.1, p = 8 x 10 -2 ). The correlation with INDIGO-MTB predictions is 241 identical for both the novel set (rank correlation R = 0.63) and for the total validation set, (R = 242 0.64 for all 36 combinations). Thus, not only can INDIGO qualitatively differentiate synergy and 243
antagonism, but it can also quantitatively separate regimens based on their extent of synergy. 244
Of note, we validated the INDIGO-MTB prediction that the combination of moxifloxacin (MXF) 245
and spectinomycin (SPC) are pairwise-antagonistic (DiaMOND FIC = 1.50) but could be made 246 more synergistic with the addition of clofazimine (CFZ) (DiaMOND FIC = 0.14). The synergy 247
identified between capreomycin (CAP) and CFZ (DiaMOND FIC = 0.70) and strong antagonism 248 between STM and moxifloxacin (MXF) (FIC = 3.68) were also experimentally confirmed. These 
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While most predictions were confirmed experimentally, there were systematic inconsistencies 278
between the model and experiment for some individual drugs. For example, half of the 279 inconsistencies arose in combinations featuring spectinomycin (SPC). Although SPC has been 280 found to synergize with several anti-TB drugs with multiple modes of action (28, 29), the model 281 tends to overpredict synergy for combinations that include SPC. This may be in part because 282 SPC predictions were based on chemogenomic data from E. coli rather than MTB response 283 transcriptomes. 284
Given the high accuracy of our model for both pairwise and multi-drug combinations, we inferred 285
interactions for 35 promising TB drugs using INDIGO-MTB. The resulting compendium of 6545 286 three-way, 52,360 four-way, and the top 100 synergistic and antagonistic combinations from 287 324,632 five-way combinations is provided as a supplement to serve as a resource for guiding 288 future drug combination screens ( Table S2, Table S3 ). 289
In vitro drug synergy is correlated with a surrogate marker of clinical efficacy 290
We next tested if in vitro drug interaction outcomes would be predictive of clinical efficacy. A 291 systematic evaluation of the clinical relevance of in vitro drug interactions on treatment efficacy 292 is lacking (30). We therefore compared INDIGO-MTB in vitro drug interaction predictions with a 293 meta-analysis of data assembled from 57 phase 2 clinical trials (31). These trials reported 294 regimen efficacy outcomes by sputum culture conversion rates of TB patients at two months. If 295 separate clinical studies reported conflicting efficacy scores for a drug regimen, we used both 296 values for comparison with INDIGO-MTB to incorporate this uncertainty. 297
We found a highly significant degree of correlation between the INDIGO-MTB interaction scores 298 and the sputum culture conversion rates for the corresponding combinations (R = -0.55 ± 0.04, 299 p ~ 10 -5 , see Figure 3A , Table S1D ). The results show that regimens predicted to have greater 300 synergy performed better in the clinical trials. For example, the INH-RIF-STM regimen (green) 301
was predicted to be synergistic in vitro, and this combination conferred high patient culture 302 negativity (~94%) at two months ( Figure 3A) . In contrast, the pairwise combinations of INH-303 STM (yellow) and INH-RIF (pink) were identified as antagonistic, and both drug pairs resulted in 304 low sputum conversion rates. There was a highly significant difference in sputum conversion 305 between synergistic and antagonistic combinations (p ~ 10 -4 , Figure 3B) , the difference in 306 clinical outcome for synergistic-additive (p = 0.038) and additive-antagonism (p = 0.016) 307
interactions were significant as well. 308
Among the combinations assessed clinically, only four two-way and two three-way drug 309 combinations had experimental in vitro drug interaction data. We next compared the correlation 310 of in vitro experimentally measured drug interaction with the corresponding sputum conversion 311
rates. We found that in vitro experimental drug interaction scores also correlated significantly (R 312 = -0.52 ± 0.1, p = 0.01) with clinical sputum conversion by sampling analysis (Figure S5) . This 
325
Despite the strong overall concordance between in vitro synergy and in vivo sputum culture 326 conversion rates, we found some outlier combinations that were inferred to be synergistic but 327 had poor clinical outcomes. All the outlier regimens contained pyrazinamide (PZA), whose 328
interaction scores were estimated based on transcriptomes that were generated under acidic 329 conditions, which were unlike the conditions of the other drug profiles. Furthermore, the RIF-330
MXF combination was identified to be antagonistic by both our model and experiments but has 331 good in vivo efficacy. It is hypothesized to be effective because of its ability to suppress 332 resistance despite being antagonistic (32 promising strategy to prioritize combination regimens. 337
Inferring molecular mediators of drug synergy 338
To interrogate what molecular processes underlie INDIGO-MTB's predictive ability, we identified 339 genes in the INDIGO-MTB model that most strongly influenced drug interaction scores. Genes 340 were in silico "deleted" from the INDIGO-MTB model (i.e., excluded from the model prediction) 341
and assigned an importance score by INDIGO-MTB proportional to their relative contribution in 342 calculating drug interaction scores. The top 500 genes sorted based on their importance score 343
accounted for 97% of INDIGO-MTB's predictive ability. We performed pathway enrichment 344 analysis using literature-curated pathways from the KEGG database (33, 34) to determine over-345
represented pathways among the top 500 informative genes (Table S1E) . Metabolic pathways 346
were highly enriched overall, and the most overrepresented pathway was oxidative 347 phosphorylation, which is targeted by BDQ. The model thus suggests that targeting this 348 pathway might have an impact on drug interaction outcomes. 349
We hypothesized that we could gain further insights into the genetic regulation of drug 350 interaction outcomes. Rv1353c as having the highest impact on drug interactions among all the TFs (Figure S6A) . 364 INDIGO-MTB estimated that Rv1353c would shift the interaction scores for almost every 365 pairwise interaction toward synergy upon induction (Δscore = -0.6±0.1). The exception was the 366 combination CFZ-STM, for which INDIGO-MTB predicted minimal interaction shift associated 367
with TF induction (Δscore = -0.2) ( Figure S6B) . 368
We tested these model predictions by comparing the interactions of three representative drug 369 combinations with the following three genetic perturbations: (1) TF induction, measured in the 370 TFI strain with the presence of chemical induction;
(2) TF disruption, measured in a knockout 371 strain (see Methods); and (3) baseline TF levels, measured in the genetic wildtype strain, 372
H37Rv and the TFI strain in the absence of chemical induction. We selected two drug 373 combinations for which strong interaction shifts were inferred upon TF induction (BDQ-STM, 374 Δscore = -0.7; CAP-STM; Δscore = -0.7), as well as the CFZ-STM combination for which the 375 model estimated minimal interaction shift. The baseline interactions between the drug 376 combinations differ substantially (BDQ-STM is additive, whereas CAP-STM and CFZ-STM are 377 both antagonistic, Figure S6C ). Figure 4 shows the difference in experimentally measured 378
interaction scores of each drug combination for the genetic perturbation conditions, relative to 379 the wildtype (Methods). The results show that when Rv1353c is induced, interactions for both 380
BDQ-STM and CAP-STM shift toward synergy (ΔFIC = -0.2 ± 0.1, p = 0.03 for BDQ-STM; ΔFIC 381 = -0.5 ± 0.2, p = 0.01 for CAP-STM), and when Rv1353c is disrupted, interactions for both BDQ-382 STM and CAP-STM shift toward antagonism (ΔFIC = 0.3 ± 0.2, p = 0.001 for BDQ-STM; ΔFIC= 383
0.2 ± 0.2, p = 0.04 for CAP-STM). In contrast, there appears to be no significant shifts in 384
interaction for CFZ-STM with either induction or disruption of Rv1353c (ΔFIC = -0.0004 ± 0.3, p 385 = 0.5 for disruption; ΔFIC= -0.03 ± 0.1, p = 0.03 for induction). Collectively, these results confirm 386
the INDIGO-MTB predictions. 387 
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Negative values indicate shifts toward synergy, and positive values indicate shifts toward antagonism.
393
The (*) and ( †) indicate that differences are significantly greater or less than zero, respectively (p < 0.05,
394
one-tailed one-sample t-test). The error bars represent the standard deviation between replicates.
395
DISCUSSION
396
Here, we constructed an INDIGO-MTB model to predict in vitro synergy and antagonism of anti-397 tuberculosis drug combinations using transcriptomics data. Our model complements existing 398 experimental strategies by increasing throughput and by identifying potential drug interaction 399 mechanisms. Our analysis using INDIGO-MTB revealed novel synergy between clinically 400
promising drug combinations, uncovered the role of the TF Rv1353c in influencing drug 401
interaction outcomes, and found a significant association between in vitro drug interaction 402 outcomes and clinical efficacy. These results suggest that using INDIGO-MTB to identify 403 synergistic regimens is a promising strategy for prioritizing combination therapies. While 404 significant challenges exist, constructing a high-quality model of drug interactions in vitro is the 405 first step towards inferring in vivo efficacy. No theoretical method currently exists that can 406 comprehensively screen thousands of combinations even in vitro. The significant correlation 407 between INDIGO interaction scores with both in vitro data and clinical efficacy data supports the 408 utility of our approach. 409
INDIGO-MTB outperforms existing strategies in terms of throughput. The largest studies in MTB 410
have so far analyzed up to two hundred unique drug combinations (37). Here, we have 411 estimated outcomes for 13,366 pairwise and 721,764 three-way combinations of 164 drugs with 412 significant accuracy based on our prospective validation. While many of the drugs might have 413
poor anti-TB activity on their own, they may greatly enhance synergy when added to existing 414 regimens. For example, we found chlorpromazine, originally used for treating psychiatric 415 disorders, synergizes with BDQ, resulting in four-fold reductions in inhibitory concentrations 416 (Figure S7A) . Thus, INDIGO can facilitate repurposing of drugs to treat TB. 417
INDIGO complements other preclinical methods such as mouse models in prioritizing regimens 418
for clinical evaluation. A systematic comparison across multiple mouse studies is challenging 419
due to the lack of quantitative raw data and variation in metrics reported in the literature. 420
Nevertheless, combinations identified by INDIGO to be highly synergistic (top 0.01%, Table S2 , 421  Table S3 ) were also found to be highly efficacious in recent mouse studies. Combinations 422 involving BDQ and CFZ alone or in a three-drug combination with PZA, Ethambutol (EMB), RIF, 423 or INH were all found to be synergistic by INDIGO and showed high bactericidal activity in 424 mouse models (5, 38-40). Four-way drug combinations involving BDQ, CFZ and PZA with EMB 425 or SQ109 were also synergistic in mouse studies (5, 38-40). In addition to these combinations 426 studied in mouse models, INDIGO-MTB also uncovered highly synergistic novel 4-drug and 5-427 drug combinations that are promising candidates for pre-clinical evaluation, such as the 428 combination with BDQ, CFZ, RIF, CLA and the anti-malarial antifolate compound P218, and a 4-429 drug combination involving BDQ, RIF, PA824, and the anti-psychotic drug thioridazine ( mediating drug interactions may be partially epistatic in nature. Collectively, this suggests that 456 knowledge of the underlying mechanism of drug interaction can be used to engineer synergy 457 between combination regimens. Our approach provides a rational strategy to identify genetic 458 targets that enhance synergy between existing regimens and introduces a potentially new way 459 to engineer effective regimens by modifying the interactions between the constituent drugs. 460
While the INDIGO approach has demonstrated significant utility in predicting synergy and 461 antagonism of drug combinations, it nevertheless has several key limitations. The correlation observed in the current study, wherein the model was constructed using MTB 468 response transcriptomes elicited by drug exposure, is higher than the correlation observed in 469 our prior study, which used chemogenomic data to infer interactions (R = 0.62 for pairwise and 470 0.64 for three-way interactions for the current study, versus R = 0.52 for pairwise and 0.56 for 471 three-way interactions in the E. coli chemogenomic study (14, 51)). Notably, while predictions 472 using E. coli data were statistically significant, many of the incorrect predictions from our model, 473
such as drug combinations involving spectinomycin, might be attributed to challenges of 474 extrapolating predictions from E. coli using gene orthology information alone. Our results 475
suggest that gene expression changes encapsulate molecular response information that is as 476
informative of drug interaction phenotypes as gene deletion studies. The updated INDIGO 477 approach can hence be applied to other pathogens that lack chemogenomic data. With reduced 478 sequencing costs, transcriptomics data is unlikely to be a substantial limitation in the future. 479
Further, while the number of possible combinations increases exponentially with the number of 480 drugs, the number of transcriptomes required only increases linearly. Finally, while synergy is associated with a better treatment outcome on average, other factors 495 such as resistance evolution, toxicity, and drug pharmacokinetics will also influence treatment 496
success. In addition, there is considerable heterogeneity in clinical trial efficacy based on patient 497 population, dose and location. The curation of numerous clinical studies and ability to predict 498 interactions in high throughput provided us with sufficient statistical power to test the association 499 between synergy and in vivo efficacy despite this heterogeneity. In the future, incorporating 500 additional factors associated with drug behavior in the host may further improve the correlation 501 between model predictions and clinical outcomes. 502 503 METHODS 504
Culture conditions 505
MTB strains were cultured in Middlebrook 7H9 with the oleic acid, bovine albumin, dextrose and 506 catalase (OADC) supplement (Difco), and 0.05% Tween80 at 37 °C under aerobic conditions 507
with constant agitation to mid-log phase, as described previously (35, 52). Strains containing the 508 anhydrotetracycline (ATc)-inducible expression vector were grown with the addition of 50 μg/mL 509 hygromycin B to maintain the plasmid. To induce expression of the transcription factor Rv1353c, 510
20ng/uL of ATc was added to the culture media. Growth was monitored by the optical density at 511 600 nm (OD600). 512
The Rv1353c overexpression strain was generated previously (35, 36). Briefly, the Rv1353c 513 gene was cloned into a tagged, inducible vector that placed the gene under control of a 514
tetracycline-inducible promoter (53) and added a C-terminal FLAG epitope tag. This construct 515 was transformed into MTB H37Rv using standard methods. The strain is available from the BEI 516 strain repository at ATCC ((54), NR-46512). 517
Phage Knockout Strain Generation 518
The H37Rv ΔRv1353c strain was constructed by a specialized transduction method(55) using a 519 gene-specific specialized transducing phage phasmid DNA provided by the Jacobs lab and the 520 previously described protocol (55). Briefly, high-titer phage stocks were generated by 521
transfecting the phasmid DNA into Mycobacterium smegmatis mc 2 155 at 30°C, and growing the 522 resulting phage plaques on an agar pad with a lawn of mc 2 155. Transduction-competent H37Rv 523
was incubated with high-titer phage stock for 24 hours at 37°C, and the transduced bacteria 524
were plated on 7H10 supplemented with 50 μg/mL hygromycin B to select for deletion-525 substitution mutants. wells. On each plate, control wells for each of the strains studied were included, containing: 1) 532 no drug and 1% DMSO vehicle; and 2) 1% culture and no drug with 1% DMSO vehicle, to 533 measure viability in the absence of drug exposure. 534
For drug susceptibility assays to measure the MIC, serial 2-fold dilutions of an individual drug 535
were arrayed in the different columns. For checkerboard drug interaction assays, 2-fold dilutions 536 of the first drug were arrayed in the columns and 2-fold dilutions of a second drug were arrayed 537 in the rows. 538
Plates were incubated at 37°C for 7 days. Cellular viability was assayed on day 7 by the 539
BacTiter Glo (Promega, Madison, WI) and Alamar Blue cell proliferation assays (Bio-Rad, 540
Hercules, CA) according to manufacturer recommendations. Briefly, we added 20µL of culture 541 from each well to 20µL of BacTiter-Glo Microbial Cell Viability Assay Reagent, incubated at 542 room temperature protected from direct light for 20 minutes, and read luminescence intensity 543 using a FluoStar Omega plate reader (BMG Lab Tech, Cary, NC). For Alamar Blue, we added 544 20µL of Alamar Blue reagent to 180µL of culture, incubated for 12 hours protected from direct 545 light, and read fluorescence intensity at emission wavelength 590nm after excitation at 544nm. 546 Figure S7B shows the strong concordance between the two methods -BacTiter-Glo and 547
Alamar Blue. 548
For drug susceptibility assays, the MIC was determined as the lowest drug concentration that 549 resulted in MTB viability comparable to the 1% culture control. For checkerboard assays, the 550 drug interaction was quantified by the Fractional Inhibitory Concentration (FIC) index, equal to: 551 , where C A is the concentration of drug A when combined with drug B yielding 552
an iso-effective inhibition comparable to the MIC, and C B is the concentration of drug B when 553 combined with drug A yielding an iso-effective inhibition. The value for FIC can be extended to 554 any arbitrary number of drug combinations as follows 555
556
Each MIC and checkerboard experiment was performed 2 times, with 2 biological replicates per 557 experiment. The mean FIC index across all iso-effective concentrations was calculated for each 558 biological replicate to determine reproducibility, and data across biological replicates were 559
summarized by averaging (Figure S1) . 560
DiaMOND drug-drug interaction experiments 561
DiaMOND drug interaction experiments were performed in biological triplicate as previous 562 described (6). Rather than sampling the entire set of dose combinations used in a traditional 563 checkerboard assay, DiaMOND samples a subset of dose responses and approximates the 564 shape of the contour of the chosen phenotype (e.g. where 50% growth inhibition is observed, 565 IC50). For example, a two-drug combination requires three dose responses (each individual 566 drug dose response and an equipotent drug combination dose response) rather than the entire 567 set of possible dose combinations. 568
Individual drug dose response ranges were chosen for each drug such that the IC50 dose was 569 close to the center and doses were linearly spaced to provide high resolution IC50 570 determination. Drug combination dose response ranges contained equipotent mixtures of two or 571 three drugs (e.g. a two-drug combination would contain ½ of the IC50 dose for each drug and a 572 three-drug combination would contain ⅓ of the IC50 of each drug). 573
Briefly, MTB strain H37Rv cultures were grown to mid-log phase (OD600 ≈ 0.6), diluted to 574 OD600 ≈ 0.05 and added to drug containing plates. Drugs were dispensed into 384-well plates 575 using a digital drug dispenser (D300e Digital Dispenser, HP) and 50 μL diluted MTB cultures 576
were overlaid. Drug treatment plates were incubated in humidified containers for 5 days at 37 °C 577 without agitation. Growth was measured by OD600 using a plate reader (Synergy Neo2, 578
Biotek). Two technical replicates were performed, and the average of each technical replicate 579 was used to calculate FIC scores. 580
The FIC for a drug combination was calculated as the ratio between the observed and expected 581 IC50 dose of the drug combination as previously described (6). FICs from each of three 582 biological replicates were calculated to determine reproducibility, and data across biological 583
replicates were summarized by averaging. Briefly, the growth measurements were normalized 584 (background subtracted, normalized to untreated) and the observed IC50 doses were calculated 585
for each individual and combination drug dose response. The expected IC50 dose for the drug 586 combination was then calculated using the IC50 of the individual drugs, based on the null 587 hypothesis that the interaction is additive. For two-drug combinations the expected IC50 dose is 588 defined as the intersection of the line (additivity line) drawn between the IC50 doses for each 589 individual drug. For three-drug combinations, the expected IC50 dose is defined as the 590 intersection of the drug combination dose response and the plane (additivity plane) created by 591
connecting the IC50 doses for each individual drug (Figure S1) . 592
RNA-seq transcriptome profile data generation 593
To profile the MTB transcriptome response to exposure of individual drugs, cultures were diluted 594 to OD600 ~ 0.2 (equivalent to 10 8 colony-forming units (CFU)/mL) and exposed to a minimum 595 inhibitory concentration (MIC)-equivalent dose of drug for approximately 16 hours. 596 RNA was isolated from these cultures as described previously (35, 52). Briefly, cell pellets in 597
Trizol were transferred to a tube containing Lysing Matrix B (QBiogene) and vigorously shaken 598 at maximum speed for 30 s in a FastPrep 120 homogenizer (QBiogene) three times, with 599 cooling on ice between shakes. This mixture was centrifuged at maximum speed for 1 min and 600 the supernatant was transferred to a tube containing 300 μL chloroform and Heavy Phase Lock 601
Gel (Eppendorf), inverted for 2 minutes and centrifuged at maximum speed for 5 minutes. RNA 602 in the aqueous phase was then precipitated with 300 μL isopropanol and 300 μL high salt 603
solution (0.8 M Na citrate, 1.2 M NaCl). RNA was purified using a RNeasy kit following the 604 manufacturer's recommendations (Qiagen) with one on-column DNase treatment (Qiagen). 605
Total RNA yield was quantified using a Nanodrop (Thermo Scientific CA). The sequencing generated an average of 75 million base-pair paired-end raw read counts 617 per library. 618
Read alignment was carried out using a custom processing pipeline that harnesses the Bowtie 2 619
utilities(56, 57), which is available at https://github.com/sturkarslan/DuffyNGS, and 620 https://github.com/sturkarslan/DuffyTools. The RNA-seq data profiling response to drug 621 exposure generated for this study are publicly available at the Gene Expression Omnibus 622
(GEO) at GSE119585. 623
Gene expression data analysis 624
The RNA-seq transcriptome profiling data that we generated were supplemented with 625 microarray and RNA-seq transcriptome profiling datasets from literature that were downloaded 626 from GEO, along with associated gene accession identifiers. The log 2 -transformed fold change 627
values of average gene expression in each treatment group were determined for all studies, 628
relative to the experiment's negative control. All genes that significantly change by more than 2-629 fold (up or down) after each drug treatment were used as input features for INDIGO-MTB. The 630
results are robust to the thresholds chosen for finding differentially expressed genes ( Table  631 S1G). 632
ComBat (18) normalization was used to minimize batch effects in the data, which uses empirical 633
Bayes approach to estimate each batch's corrected mean and variance. The effectiveness of 634 normalization was checked using principal component analysis. This version of the 635 transcriptomic/chemogenomic matrix represented the drug-gene network that was required to 636 build the INDIGO-MTB model. 637
The drug-gene interaction profiles for each drug are then used by INDIGO to create a "joint" 638 interaction profile for a drug combination (Figure S1 ). INDIGO assumes that cellular response 639
to drug combinations is a linear function of the cellular response to individual drugs. This 640 assumption is based on prior experimental studies that found that a linear model best explained 641 transcriptional response of cells treated with drug combinations (58, 59). Further, in our prior 642 study in E. coli, we found that other models of profile integration, such as correlation or profile 643 overlap performed poorly in predicting drug interactions compared to the linear integration 644
model (14). 645 646
Quantifying drug-drug interaction scores for model training 647
To train INDIGO-MTB, checkerboard FIC indices of drug combinations were collected after 648
conducting literature search (n=140). We also included FIC50 indices that were calculated using 649
the DiaMOND approach (n=62)(6). Since the DiaMOND study had a distinct distribution from 650 other checkerboard studies from literature (Mean = 1.05 and 0.99, Standard deviation = 0.32 651 and 0.81 for DiaMOND and checkerboard respectively), we statistically transformed the 652
DiaMOND scores so that the overall distribution of the DiaMOND-measured scores had the 653 same mean and standard deviation as the remaining checkerboard datasets. The normalized 654 scores were used for training INDIGO-MTB (Table S1F) . Similarly, the DiaMOND data 655 generated in this study for validation was normalized using the same approach prior to 656 comparison with INDIGO-MTB predictions. The average interaction score in the final training set 657 was 1.01, suggesting that the training data set is not significantly biased towards synergy or 658
antagonism. 659
Statistical Analyses 660
Our experimental test set is sufficiently powered statistically to significantly assess the accuracy 661 of INDIGO's correlation with the experimental data. For example, the probability of getting a 662 correlation of 0.62 achieved by INDIGO by random chance is less than 1 in 10 3 . We statistically 663 estimated that we only need 14 samples to detect a correlation of 0.6 (R>=0.6) with a p-value of 664 0.01. Our test set sample size is significantly larger than this number. 665
Spearman rank correlations were computed using the statistical software R. Differences 666
between the means of each group in box plots were compared using two-sample one-tailed K-S 667 tests in R. To further assess the robustness of our results to variation in clinical trials, we 668 performed sampling analysis by choosing one representative clinical trial randomly for each 669 regimen. We observed a significant correlation between predicted interaction scores and the 670 sputum culture conversion rates (mean rank correlation R = -0.38 average of 100 random 671 sampling trials) (Figure S7B) . 672
The significance of the AUC values from the ROC analysis was calculated by randomly 673
permuting the class labels (synergy or antagonism) of the test data 1000 times. The difference 674
in accuracy of the actual model with the random permuted models was compared using a t-test. 675
We used the RandomForest algorithm that is part of the Machine learning toolbox in MATLAB.
676
The regression random forest algorithm was used with default parameters for the number of 677 predictors sampled (default value -N/3, where N is the number of variables). Hyperparameter 678 tuning of parameters in the training set instead of using default parameters also resulted in a 679 similar accuracy in the test set (Table S1H ). Random forests are perfectly suited for our 680 analysis as they can achieve high accuracy even with small sample sizes and can be easily 681
interpreted. The training set used here is relatively small for deep neural networks which 682 require thousands of samples. On the other hand, SVM and decision trees can be built with 683 small sample sizes but do not achieve high accuracy as Random Forests. The accuracy using 684 these approaches with default parameters is lower than Random Forests with default 685 parameters ( Table S1H) . 686
The INDIGO-MTB model and associated data sets are available from the Synapse 687 bioinformatics repository (Synapse ID: syn18824984) (https://www.synapse.org/INDIGO_MTB) 688
(DOI: 10.7303/syn18824984). 689
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Liao, for their technical assistance, and Awanti Sambarey for her feedback on the manuscript. 698 algorithm then uses a machine learning approach called Random Forest to create a 902 mathematical model that associates the FIC score of each drug combination to its 903 corresponding joint drug-gene interaction matrix. Random Forest builds a series of decision 904 trees to identify specific patterns in the drug-gene interaction matrices that significantly 905 associate with the value of the corresponding drug-drug interaction FIC scores. (C) Once built, 906
the INDIGO-MTB model requires only the transcriptomic response profile elicited by a new 907 compound of interest as input to predict FIC scores of combinations featuring the compound of 908
interest. (D) Representative checkerboard assay experiments of a synergistic and antagonistic 909 drug pair. Cultures were exposed to serial dilutions of drugs (designated in the rows and 910 columns) for 7 days, and bacterial viability was quantified by measuring ATP levels with the 911
BacTiter Glo reagent. The thick black boxes denote the individual drug MIC wells, and the 912 boxes with numbers denote concentrations that yielded iso-equivalent inhibition (each of the 913 numbers represent the FIC score calculated based on the drug concentrations associated with 914 corresponding well). (E-F) Representative DiaMOND assay experiments of a synergistic and 915 antagonistic drug pair (E) or triplet (F). Cultures were exposed to drugs in 384-well plates and 916 growth was measured by OD600. The FIC for a drug combination was calculated as the ratio 917 between the observed and expected IC50 dose of the drug combination. For two-drug 918 combinations the expected IC50 dose is defined as the intersection of the line (additivity line) 919 drawn between the IC50 doses for each individual drug. For three-drug combinations, the 920 expected IC50 dose is defined as the intersection of the drug combination dose response and 921 the plane (additivity plane) created by connecting the IC50 doses for each individual drug. vitro interaction scores. For both experimental and model-predicted scores, values less than 0.9 948 indicate synergy, values between 0.9 and 1.1 denote additivity, and values greater than 1.1 949 indicate antagonism. Each dot indicates a specific drug combination. Dark red dots mark two-950 drug regimens (R = 0.63, p ~ 10 -4 ), and blue dots mark three-drug regimens (R = 0.68, p ~ 10 -2 ). 951
The specific combinations mentioned in the text are highlighted in the plot. (C) Dot plot of 952 experimentally measured drug interaction scores versus the INDIGO-MTB predicted drug 953 interaction type. The dots labeled in red font denote outlier combinations that were misclassified 954
by INDIGO-MTB. The interaction scores were significantly different between predicted 955 synergistic and antagonistic combinations (p = 6 x 10 -5 ). The horizontal lines in the box plot 956
represent the median and the first and third quartiles. (D) Sensitivity vs specificity curves for 957
INDIGO-MTB predictions of synergy and antagonism for both 2-drug and 3-drug combinations 958
in the validation set. The AUC values are 0.89 (p = 4 x 10 -5 ) and 0.91 (p = 4.1 x 10 -5 ) for synergy 959 and antagonism respectively. (Sensitivity = 88.4% and Specificity = 86.5% for synergy, 960 Sensitivity = 79.4%, Specificity = 90% for predicting antagonism). 
